TKIs Do Not Directly Cause Lymphoma in CML, But Rare Secondary Lymphomas Have Been Reported
While tyrosine kinase inhibitors (TKIs) are not established causative agents of lymphoma, rare case reports document secondary lymphoid malignancies developing in CML patients during long-term TKI therapy, though a direct causal relationship remains unproven.
Understanding the Evidence
The major CML treatment guidelines 1, 2, 3, 4 do not list lymphoma as a recognized adverse effect of TKI therapy. These comprehensive guidelines from ESMO, European LeukemiaNet, and NCCN extensively detail TKI toxicity profiles—including cardiovascular events, pleural effusions, hepatotoxicity, and hematologic toxicities—but lymphoma is conspicuously absent from documented adverse events 5.
Case Reports vs. Established Causation
Several recent case reports describe lymphoma development during TKI therapy:
- Diffuse large B-cell lymphoma (DLBCL) after 5 years of nilotinib (following prior imatinib and dasatinib) 6
- Non-Hodgkin lymphoma after 9 years of imatinib 7
- Follicular lymphoma after 6 years of imatinib 8
- Lymphoplasmacytic lymphoma after 15 years of TKI therapy 9
- Hodgkin lymphoma after 10 years of TKI therapy 10
Critical Caveats
These case reports acknowledge that causality remains speculative. The Naranjo algorithm score in one case was only 3, indicating "possible" but not probable causation 7. Proposed mechanisms include:
- Cumulative drug exposure effects
- Immune dysregulation from chronic TKI therapy
- Genomic instability
- CML itself as a risk factor for secondary malignancies 10
Clinical Implications
The dramatically improved survival with TKIs (85-95% overall survival at 5+ years) 1 means patients live long enough to potentially develop secondary malignancies that might have occurred regardless of TKI exposure. This is a surveillance artifact rather than proven causation.
Practical Management
- Continue TKI therapy as indicated for CML control—the survival benefit vastly outweighs theoretical lymphoma risk
- Maintain routine clinical surveillance for lymphadenopathy, B-symptoms, or unexplained cytopenias
- Investigate any suspicious findings promptly with appropriate imaging and biopsy
- If lymphoma develops, treat according to lymphoma-specific protocols; TKI discontinuation decisions should be individualized based on CML disease status and lymphoma treatment requirements 6, 7
The rarity of these case reports (handful of cases over decades of widespread TKI use) suggests this is an extremely uncommon occurrence, if causally related at all. The established benefits of TKI therapy in preventing CML progression to blast crisis—which carries >90% mortality—far exceed any theoretical lymphoma risk.